A Broad-Spectrum Multi-Antigen mRNA/LNP-Based Pan-Coronavirus Vaccine Induced Potent Cross-Protective Immunity Against Infection and Disease Caused by Highly Pathogenic and Heavily Spike-Mutated SARS-CoV-2 Variants of Concern in the Syrian Hamster ModelArticle Published on 2024-02-152024-09-05 Journal: bioRxiv [Category] update2024, [키워드] CD4+ T cells CD8+ T cells COVID-19 cross-protective pan-coronavirus vaccine SARS-CoV-2 variants of concern [DOI] 10.1101/2024.02.14.580225 PMC 바로가기 [Article Type] Article
Priming conditions shape breadth of neutralizing antibody responses to sarbecovirusesArticle Published on 2022-10-212022-11-15 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] BNT162b2 BNT162b2 vaccine breadth Breakthrough infection Cohort Combination condition cross-neutralization cross-protective dose elicit highest immunized inactivated include individual Infection magnitude mRNA multiplex neutralization Neutralization assay neutralizing antibody Neutralizing antibody response of BNT162b2 omicron public health Receptor binding domain sarbecovirus Sarbecoviruses SARS-CoV-1 SARS-CoV-1 infection SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant sera Sinopharm vaccination Vaccine Vaccine design Virus spike viruses [DOI] 10.1038/s41467-022-34038-6 PMC 바로가기
A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to OmicronArticle Published on 2022-10-062022-11-15 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 100% conserved Analysis Antigen Beta caused CD4 CD4+ CD8 CD8+ T cell clade clades composed confirmed cases conserved COVID-19 cross-protective deaths Delta epitope Epitopes Epsilon Eta Gamma Genome genomes GISAID greater highly antigenic HLA binding hydrophobic IFN-γ IL-10 IL-12 IL-2 IL-6 immune response immune responses immunoinformatics in silico approaches in vivo Lambda long-lasting majority memory Metadata molecular docking Mortality Mutation non-toxic offer omicron ORF ORF1ab ORF8 proteins peptide performed promoted Protein reduced Reinfection SARS-CoV-2 SARS-CoV-2 genome SARS-CoV-2 variants secretion severity Strains suffered T cell epitope TGF-β Th1 the Spike the vaccine TLR4 Vaccine variant variants virus virus transmission WHO Wuhan [DOI] 10.1038/s41598-022-21207-2 PMC 바로가기
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathologyArticle Published on 2022-09-292022-11-15 Journal: Vaccine [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome Adaptive immune response addition antibodies antibody Beta Cell coronavirus coronavirus disease COVID-19 COVID-19 vaccines CpG cross-protective develop feature Gamma IgA antibody IgG antibody immunopathology Infection initial intranasal intranasal vaccination intranasally investigated less lung Lung eosinophilic immunopathology Lymph node mice mucosa nasal nasal mucosa oligonucleotides pandemic potential risk Prevent Protective protective effect reducing Respiratory disease risk SARS-CoV-2 SARS-CoV-2 variant secretory secretory IgA secretory IgA antibody. serum spike-specific IgG subcutaneous vaccination subcutaneously T helper Th1 Th2 Trimeric spike protein upper respiratory tract vaccination Vaccine variant variants viral challenge virus infection viruses [DOI] 10.1016/j.vaccine.2022.08.049 PMC 바로가기
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosaArticle Published on 2022-09-072022-11-15 Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome adaptive addition anti-Spike IgG B cells Beta boost booster cellular immunity Central nervous system Complete coronavirus coronavirus disease COVID-19 COVID-19 vaccine cross-protective delta variant effective effector memory Host humoral Humoral immunity IgA Immunity immunization induce Infection inflammatory properties intranasal intranasal vaccination intranasally lentiviral lentiviral vaccine lung mice mRNA mucosa mucosal mucosal booster vaccine mucosal immunity nasal non-replicative omicron organism pandemic Protective reducing SARS-CoV-2 SARS-CoV-2 emerging variants of concern SARS-CoV-2 immunity shown specificity susceptible T cell target the SARS-CoV-2 transgenic mice vaccination vaccine candidate variant variants of concern Viral transmission waning anti-COVID-19 immunity. [DOI] 10.1016/j.ymthe.2022.04.016 PMC 바로가기
A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variantsDelta × Omicron 하이브리드 mRNA 백신의 추가 용량은 Omicron 및 기타 SARS-CoV-2 변이체에 대한 광범위 중화 항체를 생성했습니다.Article Published on 2022-07-072022-09-11 Journal: Journal of Biomedical Science [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antigenic approach booster dose CD8+ conserved COVID-19 cross-protective Cross-protectivity Delta Delta variants develop Efficacy elicited epitope feasible hybrid Hybrid vaccine Immune escape immunized Inclusion mice mRNA vaccine mRNA-based vaccine Mutation naïve Neutralizing Neutralizing antibodies neutralizing antibody new SARS-CoV-2 Next generation vaccine omicron Omicron vaccine produced RBD Receptor binding domain SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants shown specific neutralizing antibodies T cell T cell response T cell responses tested Transmission Vaccine Vaccine design Vaccines variant variants variants of concern VOCs wild type wild-type [DOI] 10.1186/s12929-022-00830-1 PMC 바로가기 [Article Type] Article
Omicron Booster in Ancestral Strain Vaccinated Mice Augments Protective Immunities Against Both Delta and Omicron Variants조상 균주 백신 접종 마우스의 오미크론 부스터는 델타 및 오미크론 변이체 모두에 대한 보호 면역 강화Article Published on 2022-07-062022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] Against antibody Antibody Response Antibody responses boost booster booster vaccination CD8 COVID-19 vaccine cross-protective cross-reactive cross-reactivity cross-reactivity. Delta DNA vaccine DNA vaccines elicited Epidemic immunized mice mice Neutralizing antibody response neutralizing antibody responses no significant difference omicron Omicron variant Omicron variants Omicron-matched vaccine RBD binding SARS-CoV-2 significant difference Specific Spike protein Spike proteins strain T cell T cell response T cell responses the spike protein Vaccine variant variants were measured Wuhan strain [DOI] 10.3389/fimmu.2022.897879 PMC 바로가기 [Article Type] Article
Investigation of the binding and dynamic features of A.30 variant revealed higher binding of RBD for hACE2 and escapes the neutralizing antibody: A molecular simulation approachA.30 변이체의 결합 및 동적 특징 조사 결과 hACE2에 대한 RBD의 더 높은 결합 및 중화 항체 탈출: 분자 시뮬레이션 접근Article Published on 2022-07-012022-09-11 Journal: Computers in biology and medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] A.30 variant ACE2 approach atomic binding binding affinity binding free energy calculated complex complexes coronavirus coronavirus disease cross-protective Deletion deletions Delta demonstrated dissociation Dissociation constant docking result domain drug Effects evade feature Free free energy global pandemic greater hACE2 help Host immune response Interaction interactions investigation mAb molecular Molecular simulation monoclonal antibodies mutated Mutation N terminal domain Neutralizing Neutralizing antibodies NTD omicron Omicron variants protein-protein docking RBD RBD complex reduce reported residue robust salt-bridge SARS-CoV-2 Simulation spike gene Spike protein Spread Substitution the spike protein variant variants variants of SARS-CoV-2 wild type [DOI] 10.1016/j.compbiomed.2022.105574 PMC 바로가기 [Article Type] Article
Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern우려되는 SARS-CoV-2 변이체에 대한 융합 억제 리포펩티드의 효능Article Published on 2022-06-282022-09-11 Journal: mBio [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] affected antibodies antiviral efficacy Beta causative agent concern conformational conserved convalescent COVID-19 cross-protective described dimeric doses effective Efficacy elicited evade expected ferret ferrets FIVE Frequency fusion inhibitor Immunity in vitro in vivo Infection Intervention less lipopeptide mechanism of action monoclonal antibody monoclonal antibody therapy monomeric neutralize Neutralizing activity Neutralizing antibodies neutralizing antibody peptide peptides postvaccination postvaccine sera potency Protein Receptor binding Receptor-binding domain reported resulting S1 subunit S2 subunit SARS-CoV-2 SARS-CoV-2 transmission SARS-CoV-2 variant selective selective pressure selective pressures sera Seven shown spike Spike protein Spread strain the receptor-binding domain therapeutic therapy vaccination Vaccine variant Viral viral entry viral evolution viral infection virus virus neutralization assays VoC VOCs Waves [DOI] 10.1128/mbio.01249-22 PMC 바로가기 [Article Type] Article
Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history백신 접종 및 감염 이력에 의한 SARS-CoV-2 Delta 및 Omicron 변이체에 대한 반응성 중화Article Published on 2022-06-102022-09-11 Journal: Genome Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] Abbott anti-S antibody antibody antibody persistence Antibody Response Antibody titre antibody titres Antigen B.1 B.1.1.529 B.1.617.2 blood sample Blood samples Cohort collected control group control groups controls COVID-19 cross-protective Delta delta variant DiaSorin dose elicited followed by generate group healthcare healthcare worker Immune escape Immunity immunoassays increasingly individuals induce Infection investigated N antigen naïve naïve subject naïve subjects natural infection neutralisation neutralising Neutralising Antibodies nucleocapsid omicron Omicron variant performed persistence Post-infection presence of antibody question reactivity required Roche S antigen SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants sera Serosurvey serum significantly subject subjects tested the SARS-CoV-2 timepoints two groups vaccinated individuals vaccination Vaccine Vaccine development variant virus VoC VOCs weakened were used while [DOI] 10.1186/s13073-022-01066-2 PMC 바로가기 [Article Type] Article